We would like to invite you to the 2018
Diabetes Summit to be held April 9-11, 2018 in Boston, MA. Our
Diabetes Summit encompasses the drug discovery and partnering aspects of
diabetes. Experts from industry and academia will discuss strategies to target Type 1 and Type 2
diabetes in presentations, panels and round-table discussions, highlight basic research, novel therapeutic targets, translation to the clinic, devices and digital aids, funding and partnering trends, emerging technologies and other relevant topics.
Focus Groups Discussions:
- Part I (Challenges and Opportunities)
- Part II (Solutions & Action Items)
Drug Discovery & Development for Diabetes:
- Opening Keynote Session - Historical Perspective & State of the Science & Industry
- Type I Diabetes - Preclinical & Clinical Development
- Type II Diabetes - Preclinical & Clinical Development
- Devices & Digital Aids in Diabetes Management
Funding, Partnering & Commercialization of Diabetes Technologies:
- Industry Partnering with Academia & CROs to Advance Diabetes Research
- Funding & Commercialization of Diabetes Technologies
- Award Ceremony & Closing Keynote Session - Predictions for the Future
- Keynote Panel Discussion
PLENARY KEYNOTE SPEAKERS
- Domenico Accili, Professor of Medicine, Columbia University
- Nir Barzilai, Professor, Department of Medicine (Endocrinology); Professor, Department of Genetics, Albert Einstein College of Medicine
- Brian Bloomquist, Senior Director, Global External Research and Development, Eli Lilly
- Andrew Young, Vice President, Chief Scientific Officer, Intarcia
DISTINGUISHED SPEAKERS
- William Bachovchin, Professor, Department of Biochemistry, Tufts University School of Medicine
- Jonathan Behr, Managing Director, JDRF
- Michael Brehm, Associate Professor, University of Massachusetts Medical School
- Alan Cherrington, Professor of Molecular Physiology and Biophysics, Vanderbilt University
- Jane Chiang, Chief Medicial Officer, Diasome Pharmaceuticals
- Joseph Cook, President and Executive Chairman of the Board, Nusirt Inc.
- Denise Faustman, Director of Immunobiology; Associate Professor of Medicine, Massachusetts General Hospital; Harvard Medical School
- Alexander (Zan) Fleming, Executive Chairman, Kinexum
- Kristoffer From, Co-founder & Chief Executive Officer, Liva Healthcare
- Robert Geho, Co-Founder and Chief Executive Officer, Diasome Pharmaceuticals Inc
- Judith Gorski, Global Director, Scientific Engagement, Crown Bioscience Inc.
- Julia Greenstein, Vice President, Research Strategy, JDRF
- Jason Hafler, Senior Director of Investments, Sanofi Ventures
- Wende Hutton, General Partner, Canaan
- Scott Johnson, Communications Lead, mySugr GmbH
- Martin Lafontaine, Commercialization Consultant, Kinexum
- David Maggs, Chief Medical Officer, Fractyl Laboratories
- Felicia Pagliuca, Vice President, Cell Biology R&D, Semma Therapeutics
- Steven Russell, Assistant Professor of Medicine, Harvard Medical School
- Aaron Schwartz, Director, R&D Innovation Sourcing, Novo Nordisk Inc.
- Donald Scott, Professor in the Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai
- Thomas Seoh, Chief Executive Officer, Kinexum
- Alain Stricker-Krongrad, Chief Scientific Officer, Sinclair Research Center
- Maria Trujillo, Principal Scientist, Quantitative Pharmacology and Pharmacometrics, Merck & Co.
- Michael Zemel, Founder and Chief Scientific Officer, Nusirt Inc.
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Venue
Hyatt Regency Boston1 Ave De Lafayette
Boston, MA 02111
1-617-912-1234
Discounted Group Rate: $269.00/night
Discount Deadline is March 16, 2018
Toll Free Reservations Phone Number: 1-888-421-1442
Mention GTCbio Event for the discounted group rate.
Book your room online using this link:
https://aws.passkey.com/go/gbio
